Pal, Sumanta
Gong, Jun
Mhatre, Shivani K.
Lin, Shih-Wen
Surinach, Andy
Ogale, Sarika
Vohra, Rini
Wallen, Herschel
George, Daniel
Funding for this research was provided by:
F. Hoffmann-La Roche
Article History
Received: 23 January 2018
Accepted: 14 May 2019
First Online: 7 June 2019
Authors’ information
: Not applicable
: This study used Truven MarketScan retrospective administrative claims data. Data were de-identified and comply with the Health Insurance Portability and Accountability Act and the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Thus, Institutional Review Board approval was not required, and formal informed consent was not obtained.
: Not applicable.
: SP reports honoraria and a consulting/advisory role with Novartis, Astellas, Aveo, Bristol-Myers Squibb, Eisai, Exelixis, Ipsen, Myriad Pharmaceuticals, Pfizer and Roche/Genentech and honoraria and research funding from Medivation. AS is employed by Genesis Research and reports a consulting/advisory role with Roche/Genentech. SKM, SW and SO are employees of Genentech, Inc. and own Roche stock. DG reports consulting/advisory roles with Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Clovis, Exelixis, Genentech/Roche, Innocrin, Janssen, Myovant, Pfizer and Sanofi and received research funding from Astellas, Bayer, Innocrin, Janssen, Novartis and Pfizer. HW is a former employee of Roche/Genentech. RV was a paid intern at Roche/Genentech at the time of the study. JG declares that he has no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.